Optimized Blanching Reduces the Host Cell Protein Content and Substantially Enhances the Recovery and Stability of Two Plant-Derived Malaria Vaccine Candidates by Stephan Menzel et al.
fpls-07-00159 February 15, 2016 Time: 14:27 # 1
ORIGINAL RESEARCH




University of Verona, Italy
Reviewed by:
Eva Stoger,
University of Natural Resources
and Life Sciences, Austria
Linda Avesani,





This article was submitted to
Plant Biotechnology,
a section of the journal
Frontiers in Plant Science
Received: 15 November 2015
Accepted: 30 January 2016
Published: 17 February 2016
Citation:
Menzel S, Holland T, Boes A,
Spiegel H, Bolzenius J, Fischer R
and Buyel JF (2016) Optimized
Blanching Reduces the Host Cell
Protein Content and Substantially
Enhances the Recovery and Stability
of Two Plant-Derived Malaria Vaccine
Candidates. Front. Plant Sci. 7:159.
doi: 10.3389/fpls.2016.00159
Optimized Blanching Reduces the
Host Cell Protein Content and
Substantially Enhances the Recovery
and Stability of Two Plant-Derived
Malaria Vaccine Candidates
Stephan Menzel1, Tanja Holland1, Alexander Boes2, Holger Spiegel2,
Johanna Bolzenius3, Rainer Fischer1,2,3 and Johannes F. Buyel1,3*
1 Integrated Production Platforms, Fraunhofer-Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany,
2 Plant Biotechnology, Fraunhofer-Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany, 3 Institute for
Molecular Biotechnology, RWTH Aachen University, Aachen, Germany
Plants provide an advantageous expression platform for biopharmaceutical proteins
because of their low pathogen burden and potential for inexpensive, large-scale
production. However, the purification of target proteins can be challenging due to issues
with extraction, the removal of host cell proteins (HCPs), and low expression levels. The
heat treatment of crude extracts can reduce the quantity of HCPs by precipitation thus
increasing the purity of the target protein and streamlining downstream purification. In
the overall context of downstream process (DSP) development for plant-derived malaria
vaccine candidates, we applied a design-of-experiments approach to enhance HCP
precipitation from Nicotiana benthamiana extracts generated after transient expression,
using temperatures in the 20–80◦C range, pH values of 3.0–8.0 and incubation times
of 0–60 min. We also investigated the recovery of two protein-based malaria vaccine
candidates under these conditions and determined their stability in the heat-treated
extract while it was maintained at room temperature for 24 h. The heat precipitation of
HCPs was also carried out by blanching intact plants in water or buffer prior to extraction
in a blender. Our data show that all the heat precipitation methods reduced the amount
of HCP in the crude plant extracts by more than 80%, simplifying the subsequent DSP
steps. Furthermore, when the heat treatment was performed at 80◦C rather than 65◦C,
both malaria vaccine candidates were more stable after extraction and the recovery of
both proteins increased by more than 30%.
Keywords: blanching, design of experiments, downstream processing, heat precipitation, host cell proteins,
plant-derived biopharmaceuticals, vaccine development
Abbreviations: BSA, bovine serum albumin; Comp, cOmplete protease inhibitor cocktail; DoE, design of experiments; DSP,
downstream processing; ER, endoplasmic reticulum; GMP, good manufacturing practice; HCP, host cell protein; OD600 nm,
optical density at a wavelength of 600 nm; Phen, 1,10 phenanthroline; QbD, quality by design; rpm, revolutions per minute;
RT, room temperature; TSP, total soluble protein; USP, upstream production; YEB, yeast extract broth.
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INTRODUCTION
Plants have been used to produce biopharmaceutical proteins
for more than 25 years (Hiatt et al., 1989). Even though plant-
based expression platforms offer inexpensive USP, scalability
and a low human pathogen load (Commandeur et al., 2003;
Schillberg et al., 2005; Fischer et al., 2012), only two products had
received regulatory approval by 2015 and only one is currently
on the market (Yusibov and Rabindran, 2008; Pastores et al.,
2014). One reason for the delayed transition from concept to
market is the erstwhile lack of regulatory guidance, which has
been addressed by the authorities only in the last few years
(CPMP, 2002; FDA, 2002; Fischer et al., 2012; Buyel et al.,
2015b). The recombinant protein expression levels that can be
achieved in plants were initially low, but have now reached
the gram product per kilogram biomass range (Bendandi et al.,
2010; Buyel, 2015). Combined with these improvements in
USP, the often challenging purification of target proteins from
plant extracts (Buyel and Fischer, 2014d) means that DSP can
account for up to 80% of the total production costs (Wilken
and Nikolov, 2012). This issue is especially pressing if no affinity
purification step is available. Therefore, several genetic fusion
tags have been developed to facilitate the purification of target
proteins, including elastin-like polypeptides (Phan et al., 2013),
hydrophobins (Reuter et al., 2014), and oleosin (Markley et al.,
2006). However, the fusion tags can affect the functionality of
the product and the fusion proteins attract regulatory scrutiny
(Fischer et al., 2012). Process-based purification approaches
solely exploiting the different intrinsic properties of the products
and HCPs are therefore more appealing and should offer a higher
success rate.
Methods for selective product extraction (Turpen, 1999),
secretion (Drake et al., 2009), and precipitation (Holler et al.,
2007) have been developed along with strategies to remove
HCPs, e.g., by low-pH extraction (Azzoni et al., 2002; Hassan
et al., 2008; Buyel and Fischer, 2014d). Recently, the heat
treatment of intact leaves in water baths (blanching) and the
heating of plant extracts (Buyel and Fischer, 2014e; Buyel et al.,
2014; Voepel et al., 2014; Beiss et al., 2015) have been used
to selectively precipitate tobacco HCPs, increasing the initial
purity of vaccine candidate proteins several fold. This facilitates
subsequent recovery (Winkelnkemper and Schembecker, 2010)
and reduces DSP costs. Specifically, there are no ‘platform’
ligands available for the purification of vaccine candidate
proteins by affinity chromatography, analogous to the protein
A ligands used to capture antibodies. Therefore, a combination
of conventional chromatography steps, e.g., ion exchange
chromatography, must be used for purification, typically aiming
to exceed a final purity of 95% (m/m; Betancourt et al., 2007;
Okuno et al., 2011; Buyel et al., 2012). This level of purity
can be facilitated by the heat precipitation of otherwise highly
abundant HCPs that can interfere with chromatography (Buyel
and Fischer, 2014d). This approach also reduces manufacturing
costs, which are especially important for products that will
be predominantly used in developing countries, e.g., malaria
vaccines. An overview of a DSP process using blanching is shown
in Figure 1.
FIGURE 1 | Continued
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FIGURE 1 | Continued
Comparison of purification processes without heat treatment (A) and
with blanching (B). With the exception of the initial blanching steps, the
process schemes are largely identical during extraction, clarification and
concentration, but the size of the capture column can be reduced to reflect
the depletion of HCPs. Also, the higher starting purity after extraction allows
the number of chromatography-based purification steps to be reduced.
UF/DF, ultrafiltration/diafiltration; Q, quaternary ammonium ligand (an anion
exchange resin); SP, sulfopropyl (a cation exchange ligand); SEC, size
exclusion chromatography.
Together with tuberculosis and HIV, the poverty-related
infectious disease malaria (caused by the parasite Plasmodium
falciparum) remains a major burden for developing countries,
accounting for 660 000–1 200 000 deaths worldwide, mostly
affecting children in sub-Saharan Africa (Murray et al., 2012).
Even though the first malaria vaccine, a PfCSP-based vaccine
addressing the pre-erythrocytic stage of the parasite (Mosquirix,
developed by GSK), has completed phase III clinical trials (Wilby
et al., 2012), it has not been recommended for widespread
deployment by the World Health Organization (Callaway and
Maxmen, 2015). Thus, we still not only lack a vaccine but also
a formulation that can induce long-lasting protection in all
vaccinated individuals.
The life cycle of the P. falciparum parasite is characterized
by three major stages: the pre-erythrocytic stage (divided into
the sporozoite and liver phases), the blood (asexual) stage and
the sexual stage. These three stages occur in two different hosts:
humans and mosquitoes. Starting from a healthy individual
(Figure 2A), the pre-erythrocytic stage of the infection is
initiated by a bite from an infected female Anopheles sp.
mosquito and the release of P. falciparum sporozoites into the
skin and later into the blood of a human host (Figure 2B).
The sporozoites are taken up by hepatocytes, resulting in the
development of merozoites, which are released into the blood
following hepatocyte rupture. The blood stage of the infection
is characterized by a repetitive cycle of erythrocyte invasion,
parasite replication and erythrocyte rupture, as well as the
release of new merozoites. The clinical symptoms of malaria are
stringently linked to this stage (Figure 2C). Only a small number
of blood-stage parasites convert into the sexual form of the
parasite (gametocytes) and can be taken up through a blood meal
into a new mosquito host (Figure 2D). The sexual phase of the
life cycle is initiated by the fusion of female and a male gametes
resulting in the formation of oocysts. Sporozoite development
in the oocysts perpetuates the life cycle and leads to multiple
transmissions of the infection within a human community due
to subsequent mosquito bites (Figure 2E; Ouattara and Laurens,
2015).
For the prevention of poverty-related diseases, millions of
vaccine doses need to be produced at low cost (Waheed et al.,
2012). Plant-based expression systems have the potential to
match these requirements (Rybicki, 2010) and vaccine candidate
antigens from several viral, bacterial and protozoan pathogens
have been produced successfully using such platforms (Daniell
et al., 2001; Clemente and Corigliano, 2012). The first plant-
derived malaria vaccine candidate has recently commenced a
phase I, dose escalation, first-in-human study (ClinicalTrials.gov
Identifier: NCT02013687). Even so, the establishment of plant-
based systems as a common production platform for vaccines is
still hampered by issues with yields, DSP efficiency and regulatory
compliance (Fischer et al., 2013).
In this DoE study we describe the optimization of DSP
for a new pre-erythrocytic malaria vaccine candidate fusion
protein (C9S) and a transmission-blocking vaccine candidate
(FQS). Both proteins were produced by transient expression
in Nicotiana benthamiana plants using the Agrobacterium
tumefaciens vacuum infiltration method (Simmons et al., 2009).
C9S is an optimized version of the CCT fusion protein, which
has been developed and characterized as a heat-stable pre-
erythrocytic malaria vaccine candidate (Voepel et al., 2014) and
included as the pre-erythrocytic component of a plant-derived
FIGURE 2 | Schematic overview of the Plasmodium falciparum life cycle in the context of human infection and transmission. The three main stages are
indicated by colored boxes. Gray indicates healthy status whereas pink indicates infected status is. Different forms of the parasite are shown in yellow. Target points
of the vaccine components are indicated by arrowed boxes. (A) Healthy individual. (B) Infection of liver cells after a mosquito bite. (C) Manifestation of blood-stage
parasitemia. (D) Formation of gametocytes initiating the sexual stage. (E) Parasite transmission within a human community.
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multi-component, multi-stage malaria vaccine cocktail (Boes
et al., 2015). The “C” component of C9S comprises two TSR-
domains from PfCSP and PfTRAP as well as the PfCeltos
antigen. This facilitates the induction of antibodies against the
pre-erythrocytic stage of P. falciparum, potentially reducing the
infection of liver cells and thereby the proliferation of the
parasites within the liver. The components “9” and “Q” of
C9S and FQS, respectively, are included to elicit blood-stage
antigen-specific antibodies, preventing or reducing blood-stage
parasitemia. The “F” component of FQS features a fusion protein
of two transmission-blocking antigens from the sexual stage of
the parasite, which are known to induce antibodies with strong
transmission-blocking activity in vitro and in animal models
(Beiss et al., 2015).
The FQS vaccine candidate is an optimized version of
the F0 variant containing an additional epitope from a
P. falciparum blood-stage antigen. The heat-stable fusion
protein F0 has previously been included as the transmission-
blocking component in the plant-derived multi-component,
multi stage malaria vaccine cocktail mentioned above (Boes
et al., 2015). Vaccines targeting each of the three stages in the
parasite life cycle are promising candidates to increase overall
protective efficacy by preventing or reducing the rate of primary
infection (pre-erythrocytic stage), the manifestation of clinical




DNA sequences encoding the fusion proteins C9S and FQS
were obtained as synthetic genes (codon optimized for
N. benthamiana) from Geneart (Thermo Fisher Scientific,
Waltham, MA, USA). C9S comprises the pre-erythrocytic-stage
antigens PfCelTOS (PF3D7_1216600, F25-D182), PfCSP_TSR
(PF3D7_0304600, P311-S383), PfTRAP_TSR (PF3D7_1335900,
E239-K289; Voepel et al., 2014) and a part of the blood-
stage antigen PfRH5 (PF3D7_0424100, T353-H365; Douglas
et al., 2014). FQS contains the sexual-stage antigens Pfs25
(PF3D7_1031000, V24-T193) and an N-terminal portion of
Pfs230 (C0-fragment, PF3D7_0209000, E443-N586; Beiss et al.,
2015), and a short region of the blood-stage antigen PfRH5
(PF3D7_0424100, T353-H365; Douglas et al., 2014).
The synthetic genes were introduced into the binary plant
expression vector pTRAkc-ER at the NcoI/NotI sites (Sack et al.,
2015). The resulting ORFs encoded an N-terminal signal peptide
sequence from the heavy chain of monoclonal antibody 24 (Voss
et al., 1995) joined to the fusion protein C9S or FQS followed
by a three-alanine linker and a C-terminal SEKDEL sequence to
retrieve the protein to the ER. The final expression vectors were
verified by sequencing and then introduced into A. tumefaciens
by electroporation (Main et al., 1995).
Plant Material and Infiltration
Nicotiana benthamiana plants were cultivated in a phytotron as
previously described (Buyel et al., 2015a) at 25/22◦C day/night
temperature and 70% relative humidity. The plants were
irrigated with 1.0 g L−1 Ferty 2 Mega (Planta Düngemittel
GmbH, Regenstauf, Germany) for 15 min h−1 during the 16-
h photoperiod (140 µmol s−1 m−2, λ = 400–700 nm) and
were grown for 56 days prior to infiltration. The bacteria
(A. tumefaciens strain GV3101:pMP90RK) were pre-cultured in
sterile baﬄed Erlenmeyer flasks at 27◦C shaking at 180 rpm for
∼48 h in YEB medium (5.0 g L−1 nutrient broth, 1.0 g L−1
yeast extract, 5.0 g L−1 peptone, 5.0 g L−1 sucrose, 0.5 g L−1
magnesium sulfate heptahydrate, pH 7.0) supplemented with
50 mg mL−1 carbenicillin, 25 mg mL−1 kanamycin, and
25 mg mL−1 rifampicin. We then inoculated 2 L of PAM medium
(20 g L−1 soy peptone, 0.5 g L−1 yeast extract, 5.0 g L−1 fructose,
1.0 g L−1 magnesium sulfate heptahydrate, pH 7.0) supplemented
with 50 mg mL−1 carbenicillin and 25 mg mL−1 kanamycin
with the pre-cultures by adjusting the OD600 nm to 0.1 and
incubated the cultures for 65–72 h at 27◦C in baﬄed flasks
shaking at 160 rpm. The cultures were diluted with water and 2x
infiltration medium (1.0 g L−1 Ferty 2 Mega) to an OD600 nm
of 1.0. The pH was adjusted to 5.6 with 12 M hydrochloric
acid before infiltration. N. benthamiana plants without roots
were then submerged in the suspension and subjected to a
vacuum of 100 mbar for 1 min. The vacuum was released
rapidly, non-infiltrated leaves were removed and the plants
were drained briefly before transfer to an incubation chamber.
After infiltration the plants were incubated under constant light
(3× L58W/830 and 3× L58W/840; Osram Licht AG, Munich,
Germany; 50 µmol s−1 m−2) for 5 days at ∼25◦C and 70%
relative humidity.
Design of Experiments
Design Expert v9.0 (Stat-Ease, Minneapolis, MN, USA) was used
to set up and evaluate the heat precipitation experiments in the
extract and by blanching. Response surface models with 60 or 29
runs were used to characterize the heat precipitation experiments
involving C9S and FQS, respectively. We investigated heating
temperatures of 20–80◦C, incubation times of 0–60 min, and
a subsequent storage time at a RT of ∼20◦C for up to
24 h in the case of C9S. Based on these results, the heat
precipitation temperature was varied in the 65–80◦C range
for FQS. The amount of target protein per gram biomass
was used as the response and normalized to the amount of
target protein measured after heat precipitation at 80◦C, with
an incubation time of 5 min and a storage time of 0 h to
compensate for batch-to-batch variations. A detailed description
of the DoE approach is provided elsewhere (Buyel and Fischer,
2014a).
We characterized the blanching of intact leaves using
I-optimal response surface designs with 52 and 26 runs for
C9S or FQS, respectively. We investigated sodium phosphate
concentrations of 0−40 mM in the blanching fluid, conductivities
between 0.0162 (pure water) and 30.0 mS cm−1 adjusted with
sodium chloride, the influence of the blanching time between 0.5
and 5 min and a storage time at RT of 0–24 h. The blanching
was conducted at 80◦C and the amount of target protein per
gram biomass was normalized to the amount of target protein
measured after 5 min blanching time, 40 mM sodium phosphate,
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a conductivity of 6.29 mS cm−1 resulting from the dissolved
buffer and no storage at RT.
I-optimal response surface designs with 20 runs were used
to study the pH stability of C9S and FQS. We adjusted the pH
of heat-treated extract in the range 3.0–7.0 and monitored the
amount of target protein per gram biomass over 24 h when stored
at temperatures in the range 8–20◦C.
Heat Precipitation and Protein Extraction
Blanching
For blanching, a previously described procedure (Buyel
et al., 2014) was used with modifications. Whole infiltrated
N. benthamiana plants (∼100 g) without roots were plunged for
up to 5 min into a pre-heated and agitated vessel containing 5 L of
water or 40 mM sodium phosphate buffer, pH 8.0. The blanching
temperature was set according to the DoE requirements. After
blanching, the plants were drained for∼15 s.
Protein Extraction
Proteins were extracted in 3 mL buffer (20 mM sodium
phosphate, pH 8.0, 10 mM sodium bisulfite, conductivity
adjusted to 15 mS cm−1 using sodium chloride) per gram of
initial fresh mass, and mixed in a blender (Waring Products, East
Windsor, NJ, USA) for 3 s× 30 s with interspersed 30 s residence
periods. A sample from each extract (∼2 mL) was centrifuged
(7 min, 16,000 × g, 4◦C). After centrifugation, the supernatant
was stored at RT for stability studies. Reduced samples for LDS-
PAGE were prepared immediately after extraction and at different
time points between 0 and 24 h.
Heat Treatment of Plant Extracts
An initial extraction was performed as described above. No
sodium bisulfite was added for the extraction of FQS. Aliquots
of 500 mL extract were transferred into a 0.78-kg, 2.0-L
custom stainless-steel vessel (height 180 mm, diameter 120 mm).
The vessel was placed in a pre-heated water bath (with a
Lauda E300 heating circulator), and 2-mL samples of the
homogenate were taken after reaching the temperatures and
incubation times stated in the DoE. During heat precipitation,
the homogenate was agitated and the temperature was controlled
using thermometers (−10 to 150◦C, VWR International,
Radnor, PA, USA; −10 to 110◦C, Carl Roth GmbH, Karlsruhe,
Germany). The homogenate was centrifuged as above and
stored for the different incubation times at RT. Samples for
quantification of target protein and TSP were prepared as
described above.
Heat Treatment during Extraction
Heated extraction in a blender was achieved by weighing
plants and filling the glass vessel of the blender with three
volumes of extraction buffer per gram biomass. The buffer and
glass vessel (without biomass) were then heated in a water
bath to ∼82◦C. Then, the vessel was placed on the blender
motor (Waring Products) and the plant material was added.
Aluminum foil was used to insulate the glass vessel. Extraction,
centrifugation, and sampling were carried out as described
above.
Measuring the pH Stability of C9S and
FQS
Plant extracts were prepared as described above but in a buffer
containing 20 mM sodium phosphate, 20 mM citric acid and
10 mM sodium bisulfite that was adjusted to pH 8.0 and a
conductivity of 15.0 mS cm−1 using sodium chloride prior to
extraction. No sodium bisulfite was added to the extraction buffer
for FQS. After extraction, heat precipitation was carried out in
a steel vessel as described above and the extract was centrifuged
(20 min, 38,400× g, 4◦C). The pH was then adjusted as required
for the DoE using 10 M sodium hydroxide or 12 M hydrochloric
acid. Aliquots of the homogenate were stored at 8, 14, and 20◦C
and samples were taken at the time points defined by the DoE.
Samples for LDS-PAGE were centrifuged (7 min, 16,000× g, 4◦C)
and immediately heated to 70◦C in LDS-PAGE loading buffer
(Thermo Fischer Scientific). Samples for TSP analysis were stored
at−80◦C.
Identification of Protease Activity
Proteins were extracted from infiltrated N. benthamiana
plants as described above and protease inhibitors were added
directly to the extract at 20◦C or after heat treatment at
50, 60, or 80◦C. We used final concentrations of 10 µM
E-64 (trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane),
1 mM phenylmethylsulfonylfluoride (PMSF), 5 µM pepstatin
and 5 mM 1,10 Phen. Alternatively, one tablet of cOmplete
protease inhibitor mix (Roche, Basel, Switzerland) was directly
dissolved in 25 mL of plant extract. Product degradation was
monitored at RT for 24 h by immunoblot analysis (see below).
Protein Quantitation
The quantity of TSP in the supernatants was determined by
the Bradford method (Simonian and Smith, 2006) using 2.5
or 5.0 µL aliquots as previously described (Buyel and Fischer,
2014c). Eight BSA dilutions in the range 0–2 mg mL−1 were used
to build a standard curve to calculate the TSP concentrations. The
target proteins were quantified in 4–12% Bis-Tris polyacrylamide
gels (Thermo Fischer Scientific) stained with SimplyBlue Safe
Stain (Thermo Fischer Scientific) and subsequent densitometric
analysis using the AIDA image analyzer software (Raytest,
Straubenhardt, Germany). Solutions of His6-tagged product
variants were used as references. These standard proteins were
purified by immobilized metal affinity chromatography (IMAC)
as previously described (Voepel et al., 2014) but with copper ions
as the ligand instead of nickel.
Product Characterization
The molecular mass and isoelectric point of C9S and FQS were
calculated from the amino acid sequence using Clone Manager
(Scientific & Educational Software, Morrisville, NC, USA).
C9S was detected using 0.4 µg mL−1 of a PfTRAP_TSR
domain-specific monoclonal antibody (Fraunhofer IME, Aachen,
Germany). FQS was detected using the reduction-sensitive
monoclonal antibody 4B7 (Malaria Research and Reference
Reagent and Resource Center, Manassas, VA, USA) diluted
1:5000 in phosphate buffered saline (PBS). A polyclonal goat
Frontiers in Plant Science | www.frontiersin.org 5 February 2016 | Volume 7 | Article 159
fpls-07-00159 February 15, 2016 Time: 14:27 # 6
Menzel et al. Blanching to Purify Plant-Derived Vaccines
anti-mouse IgG labeled with alkaline phosphatase (Jackson
ImmunoResearch, West Grove, PA, USA) was used as the
secondary antibody, diluted 1:5000 in PBS. The signal was
detected with 0.3 mg mL−1 nitro blue tetrazolium (NBT) and
0.16 mg mL−1 5-bromo-4-chloro-3-indolyl phosphate (BCIP) in
alkaline phosphatase buffer (100 mM Tris-Cl, 100 mM sodium
chloride, 5 mM magnesium chloride, pH 9.6). The target band
intensity was quantified using AIDA image analyzer software and
the corresponding His6-tagged product as a reference (42–250 ng
per lane).
RESULTS
The Properties of Malaria Vaccine
Candidates C9S and FQS and their
Expression in N. benthamiana
The C9S and FQS vaccine candidates were expressed in
N. benthamiana plants resulting in average expression levels of
92.2 ± 6.1 (n = 11) mg kg−1 and 48.9 ± 7.8 (n = 2) mg kg−1,
respectively. We predicted the sizes and isoelectric points of both
proteins based on their amino acid sequences (C9S = 35 kDa
and pI 4.7, FQS = 37 kDa and pI 4.3). As anticipated based
on these pI values, the solubility of both proteins decreased as
the pH was reduced to ∼4.0, ultimately resulting in the loss
of 85% C9S and 100% FQS at pH 3.0 (Figure 3) and causing
more of each protein to appear in the pellet fraction after
centrifugation (data not shown). The DoE evaluation revealed
a linear correlation between pH and the solubility of C9S and a
quadratic response was observed for FQS (Supplementary Tables
S1 and S2). Incubation temperature and duration did not have a
relevant effect on the solubility of either target protein.
In our initial experiments, neither target protein was detected
in samples of clarified supernatant after storage at RT for 24 h
(data not shown). Immunoblot analysis revealed that the loss of
C9S could be avoided if the extracts were heated to 60–80◦C for
5 min before storage at RT for 24 h (Figure 4A). Furthermore,
a combination of heat treatment at 50◦C and the inclusion of
certain protease inhibitors partially restored the yield of C9S to
∼9% (Phen) and ∼22% (PMSF) of the level observed after heat
treatment at 80◦C. Only PMSF preserved detectable amounts of
C9S after heat treatment at 20◦C and storage at RT for 24 h,
achieving a yield of ∼10% compared to the level observed after
heat treatment at 80◦C (Figures 4B,C). We did not conduct the
corresponding analysis of FQS.
Improving the Stability of C9S and FQS
at Neutral pH by Heat Precipitation
Based on the beneficial effect of heat treatment on target protein
yield, we decided to investigate the underlying mechanism in
more detail using a DoE approach. We used the heat precipitation
temperature and the incubation time during heat precipitation
as the major factors. Analysis of the corresponding DoE profiles
(Supplementary Tables S2 and S3) revealed that the highest yields
of C9S and FQS were achieved at incubation temperatures in the
75–80◦C range (Figure 5). The yield of FQS was not affected by
prolonged incubation times at these temperatures, but the yield
of C9S declined by ∼33% if the incubation time was increased
from 5 to 60 min. In contrast, both products were completely lost
after 24 h if the heat treatment step was carried out at less than
50◦C (C9S) or 65◦C (FQS; Figure 5).
Investigation of Different Heat
Precipitation Methods
Having established that heat treatment for 5 min at 80◦C
achieved the highest yields of C9S and FQS we set out to
investigate other heat precipitation methods that might be easier
to integrate into the production process. Therefore, we compared
heat precipitation applied to plant extracts with the blanching
of intact plants (Buyel et al., 2014) using water or buffer,
and with heat precipitation using hot buffer during protein
extraction. C9S was selected as the model protein for this
experiment. We observed no significant difference (two-sided
t-test, α level= 0.05) in the yield of C9S when we compared heat
precipitation in plant extract, blanching in buffer and extraction
in hot buffer (Figure 6A). There was also no significant loss of
product in the subsequent 24-h incubation period at RT when
using any of the three heating methods, achieving average yields
of 153.9 ± 19.2 mg kg−1 (n = 10). In contrast, no C9S was
detected in the plant extracts at any time if blanching was carried
out in water instead of buffer. Blanching in water reduced the
amount of TSP by ∼97%, resulting in a final concentration of
∼0.05 mg mL−1 (Figure 6B). The other three methods reduced
the TSP by ∼85%, again with no significant difference among
them and without the TSP concentration changing over the 24-h
incubation period. Analysis by LDS-PAGE revealed that the lower
amount of TSP in the heat-treated samples was clearly linked
to the removal of HCPs (Figure 6C), including ribulose-1,5-
bisphosphate carboxylase/oxygenase (RuBisCO). The removal of
HCPs increased the purity of C9S from 0.02 g g−1 TSP in the
untreated homogenate to 0.15 g g−1 TSP following the heat
treatment of extract, blanching in buffer or extraction in hot
buffer.
Influence of Blanching Time and Buffer
Composition on C9S and FQS Yields
Given that C9S could be extracted from plants blanched in buffer
but not from those blanched in water, we decided to investigate
the effect of buffer composition, i.e., phosphate concentration and
conductivity. We therefore set up a DoE approach including both
vaccine candidates and tested the effect of buffer composition
and the duration of blanching. The buffer concentration was the
dominant factor in the case of C9S (Supplementary Table S5) and
the highest yields of 156.4 ± 21.6 (n = 13) µg g−1 biomass were
achieved at phosphate concentrations in the range 30–40 mM.
In contrast, the phosphate concentration had a smaller impact
on the yield of FQS (Supplementary Table S6). The duration of
blanching only became important when the blanching step was
brief, i.e., both C9S and FQS were completely lost during post-
extraction storage at RT for 24 h only if the duration of blanching
was reduced to 0.5 min (Figure 7). Increasing the time to 5.0 min
restored the yield to 156.4 ± 21.6 (n = 13) µg g−1 for C9S and
50± 13.8 (n= 5) µg g−1 for FQS.
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FIGURE 3 | Response surfaces models illustrating the effect of pH, storage time and temperature on the yield of C9S (A,B) and FQS (C,D). The yield of
both target proteins decreased at lower pH values whereas incubation time and temperature had no relevant effect. At pH 5.0, the yield of FQS was higher than that
of C9S. Colors are used to indicate high (red) or low (blue) response values.
Comparison of Heat Precipitation and
Blanching
As stated above, heat treatment inhibited target protein
degradation and reduced the TSP content by more than 85%
(Figure 8B). Heat precipitation in a vessel at 65◦C achieved C9S
yields of 103.5 ± 7 (n = 3) µg g−1 biomass, increasing by 40%
to 143.6 ± 8.4 (n = 3) µg g−1 biomass at 80◦C (Figure 8A).
Similarly, blanching at 65◦C achieved C9S yields of 91.4 ± 8.4
(n = 3) µg g−1 biomass, increasing by 100% to 178.1 ± 17
(n= 3) µg g−1 biomass at 80◦C (Figure 8A). Blanching therefore
appeared to be more efficient for the recovery of C9S from
the plant biomass. In contrast, both methods removed tobacco
HCPs with similar efficiency of >85% at both temperatures, as
shown by monitoring the TSP content (Figure 8B). Immunoblot
analysis using an antibody specific for the PfTRAP_TSR domain
of C9S revealed a dominant band with an apparent molecular
mass of ∼35 kDa (Figure 8D) which was also the dominant
band on corresponding gels stained with Coomassie Brilliant
Blue (Figure 8C).
DISCUSSION
The Properties of Each Target Product
Influence DSP Development
Many tobacco HCPs have pI values greater than 6.5 (Buyel
and Fischer, 2014d). Therefore, cation exchange (CEX)
chromatography can be a useful HCP-removal step if the target
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FIGURE 4 | Effect of heat treatment and protease inhibitors on the yield of malaria vaccine candidate C9S. (A) Immunoblot of C9S using a mouse-derived
monoclonal primary antibody against PfTRAP_TSR and alkaline phosphatase labeled goat-anti-mouse secondary antibody immediately after the heat treatment of
plant extracts at different temperatures and after storage at RT for 24 h. (B,C) Immunoblots using the same antibodies as above, showing the effect of protease
inhibitors on the yield of C9S after the plant extracts were treated at different temperatures and stored at RT for 24 h. Std 1–3 denote His6-tagged protein variants
used for quantification: 83, 166, and 250 ng per lane (A) or 42 and 166 ng per lane (B,C).
protein has a pI below 6.0 and no affinity resin is available,
as was the case for our malaria vaccine candidates C9S and
FQS. CEX chromatography typically requires a buffer pH below
6.0 to work effectively (Ge Healthcare, 2010). This pH can
also be used to precipitate several tobacco HCPs, including
RuBisCO (Hassan et al., 2008; Buyel and Fischer, 2014b),
thereby increasing the purity of the product before the first
chromatography step, which can facilitate subsequent unit
operations (Winkelnkemper and Schembecker, 2010). We
therefore tested the two target proteins to determine their
stability at pH ∼7.0, which is typically used for extraction
(Hassan et al., 2008), and also in the pH range 3.0–5.0.
Unfortunately, both proteins precipitated at pH values below 5.0,
reducing the yields by 50% or more. We therefore concluded that
low-pH conditions suitable for the precipitation of HCPs and
typical for CEX loading buffers were not compatible with C9S or
FQS. Furthermore, both proteins were unstable during storage
and their concentrations fell below our detection threshold of
∼1 µg mL−1 after incubation at RT for 24 h. Indeed, losses
exceeding 50% were observed after ∼7 h, a typical duration of
a hold step prior to product capture in large-scale production
processes.
We anticipated that host cell proteases are likely to be
responsible for the observed losses so we supplemented the
plant extracts individually with E-64 to inhibit cysteine proteases,
PMSF to inhibit serine proteases, pepstatin to inhibit aspartyl
proteases and Phen to inhibit metalloproteases. PMSF, and to
a lesser extent Phen, partially inhibited the degradation of C9S
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FIGURE 5 | Response surface representations of predictive models for C9S and FQS yields after the heat treatment of plant extracts, showing
dependence on incubation temperature as well as incubation and storage durations. The yields of C9S (A–C) decreased if the heat treatment temperature
fell below 65◦C and losses increased with longer incubation and storage times. The yields of FQS (D–F) decreased if the heat treatment temperature fell below 72◦C
but neither incubation nor storage time had a relevant effect. C9S and FQS yields were normalized to a reference condition based on blanching at 80◦C for 5 min
and subsequent storage for 0 h. Colors are used to indicate high (red) or low (blue) response values.
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FIGURE 6 | Comparison of the influence of different heat precipitation methods (heat precipitation, blanching in water, blanching in buffer, heat
extraction) at 80◦C on target protein concentrations (A,C) and TSP levels (B). Target protein stability was achieved by heat precipitation in extract, blanching
in buffer and heat extraction. The band representing target protein C9S in the Coomassie-stained gel shown in panel (C) is indicated with a black arrow.
indicating that this protein is susceptible to the combined action
of serine proteases and metalloproteases, which are known to
be present in plant extracts as active enzymes (Mandal et al.,
2014).
Our previous work with malaria vaccine candidates has shown
that thermal stability can be an inherent feature of P. falciparum
surface antigens and fusions thereof, and can be exploited for
the heat-induced selective removal of tobacco HCPs in the
temperature range 60–80◦C (Buyel et al., 2014; Voepel et al.,
2014; Beiss et al., 2015). We therefore investigated whether
the heat treatment of extracts containing C9S or FQS could
remove the HCPs and inactivate the proteases at the same
time, thereby increasing the recovery and stability of the target
proteins.
Heat Precipitation of Tobacco HCPs
Increases Product Stability
Based on our earlier work, we tested the efficiency of HCP
precipitation by heating the tobacco extracts to 20–80◦C for 5–
60 min. The concentrations of C9S and FQS in extracts heated to
75–80◦C remained constant when the samples were maintained
at RT for the subsequent 24 h. However, the recovery of C9S
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FIGURE 7 | Response surface models showing how the yields of C9S (A,B) and FQS (C–F) depend on phosphate concentration in the blanching
buffer, incubation and storage times as well as buffer conductivity. A phosphate concentration of 30–40 mM resulted in the highest yields of C9S and an
incubation time of more than 0.5 min was required for the C9S to concentration to remain constant over a 24 h incubation period at RT. The phosphate
concentration did not have a relevant effect on the yield of FQS but incubation times exceeding 0.5 min were necessary to prevent product loss over the subsequent
24 h incubation period. Colors are used to indicate high (red) or low (blue) response values.
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FIGURE 8 | Comparison of blanching in buffer and heat precipitation in the plant extract. The yield of C9S increased for both methods when heat treatment
was carried out at 80◦C instead of 65◦C (A), whereas there was no difference in TSP levels at these temperatures, i.e., both methods achieved a reduction of 85%
compared to untreated extract (B). The increased yields were also observable on Coomassie-stained LDS-PAGE gels (C) and western blots using C9S-specific
primary antibody for detection (D). Hom – homogenate; Std – His6-tagged C9S variant, 390 ng per lane.
became less efficient if the heat treatment was prolonged beyond
5 min, indicating that C9S is less stable than FQS. This indicates
that heating should be kept to a minimum duration even for
proteins designed to be heat stable, because losses can occur over
time as reported for another malaria vaccine candidate, Vax8
(Buyel et al., 2014).
When we compared different heat treatment methods, we
found that they performed equally well in terms of removing
tobacco HCPs and preventing product losses due to protease
activity. However, when the blanching buffer (pH 8.0) was
replaced with water, we observed the complete loss of C9S
(but not FQS). We propose that this phenomenon ultimately
reflects the rupture of plant cell membranes, especially the
vacuolar membrane, by the osmotic shock caused by heating in
water, resulting in the homogenization of the formerly separate
intracellular compartments. The vacuole represents the largest
proportion of the cytosol by volume, accounting for ∼90% of
the total (Owens and Poole, 1979). Because the vacuole is acidic,
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the pH of the resulting cell lysate falls to ∼5.4 (Thoday and
Evans, 1932; Buyel and Fischer, 2014e), which as discussed above
causes the precipitation of C9S along with many tobacco HCPs
but leaves ∼50% of FQS in solution. The use of a buffer during
blanching prevents the pH drop caused by cell lysis and thus
avoids the precipitation of proteins such as C9S and several
HCPs that are sensitive to low pH values. This hypothesis is
supported by our observation that the pH of the blanching
buffer becomes lower as more plants are blanched, requiring
periodic readjustment to pH 8.0 (data not shown). The proposed
mechanism also explains why the yield of C9S was dependent
on the concentration of phosphate in the blanching buffer: the
higher the concentration of phosphate, the higher the buffering
capacity and thus the smaller the pH drop induced by membrane
rupture.
The membrane of the ER may also be affected by rupture
suggesting that the product could diffuse from the plant
tissue and be lost in the blanching fluid, reducing the
process yield. We found no significant difference in C9S
yields achieved with blanching in buffer, extraction in hot
buffer or heat precipitation after extraction (Figure 4A). This
indicated that if product losses occurred due to the rupture
of the ER membrane, they were negligible compared to the
experimental error of ±10% (m/m; n = 12) we observed
for the C9S concentration. We speculate that the product
yield was not affected by blanching-induced membrane rupture
because the plant tissue, including the cell wall and remaining
membrane fragments, was a diffusion barrier for the proteins
but not for the hydronium ions (H3O++) responsible for the
observable change in blanching buffer pH. The hydrodynamic
radius of hydronium ions is 0.143 nm (Choi et al., 2005),
which is smaller by a factor of 15 than the radius of a
35 kDa protein, such as C9S, which is ∼2.16 nm (Erickson,
2009).
Process Considerations for the Choice
of Heat Precipitation Method
The application of statistical experiment planning using
dedicated DoE software and thorough data analysis
allowed the rapid characterization of the different heat
precipitation methods and target protein pH stability.
The resulting descriptive models were of high quality,
i.e., R2 > 0.9 (Table 1), and were used for process
optimization.
The product yield is an important aspect to consider when
selecting a heat precipitation method. Here, the highest yields
were achieved by blanching intact plants in a buffer. Another
key issue is the ease with which a specific operation can be
integrated into a DSP, particularly an existing process. The
heating of plant extracts initially seems an appealing option
given that stirred vessels with integral heating jackets are
readily available in many laboratories. However, this approach
has several drawbacks including the large volumes of buffer
that must be heated and cooled (and the corresponding high
energy costs) and the declining surface-to-volume ratio during
scale-up, which reduces the relative heat transfer (Buyel et al.,
TABLE 1 | Quality parameters of the predictive models for heat
precipitation in extract, blanching in buffer and the pH stability of C9S and
FQS derived from DoE analysis.
Model Target
protein
R2 Adjusted R2 Predicted R2
Heat precipitation in extract C9S 0.9051 0.8903 0.8441
FQS 0.9806 0.9773 0.9688
Blanching in buffer C9S 0.9736 0.9686 0.9548
FQS 0.9763 0.9545 0.8132
pH stability C9S 0.9664 0.9624 0.9537
FQS 0.9551 0.9923 0.9836
2014). These issues do not affect blanching because this process
requires a single step to heat a defined volume of buffer,
and only a small amount of additional energy is required
to heat the plant biomass immersed in the fluid. The use
of hot buffer during extraction reduces the process time by
integrating extraction and heat precipitation. However, it can
take several minutes to add hot buffer to a blender in a
scaled-up process, so some of the biomass may be in contact
with the hot buffer for longer than anticipated, risking the
loss of sensitive products such as C9S. Cooling also becomes
more challenging at larger scales because the surface-to-volume
ratio becomes progressively smaller. In any case, knowledge
of the thermal properties of the plant biomass, i.e., specific
heat capacity and thermal conductivity is important for the
design of the equipment used for heating (Buyel et al., 2016).
This design process can be facilitated by numeric modeling
approaches that can provide valuable insights into the heat
transfer mechanisms as has been recently described for blanching
(Buyel, 2016).
Overall, blanching appeared to be the most suitable technique
for plant HCP removal. The method increased the concentration
of C9S from 2 to 15% (m/m) TSP. Hence, fewer HCPs
would be available to bind during an initial capture step, most
likely using an ion exchange resin. This would save binding
capacity for the actual target protein, potentially reducing
the column size by a factor of 7.5 and investment costs
would decline accordingly. Furthermore, the lower number
of HCP species binding during capture would facilitate
separation of the HCPs from the product because co-
elution is less likely. As a consequence, a smaller number
of purification steps would be sufficient to achieve the
required final purity. On the other hand, heat treatment
potentially has a negative impact on the capacity of depth
filters used during clarification (Buyel et al., 2014), but
countermeasures such as the use of flocculants can be
implemented to restore filter performance (Buyel and Fischer,
2014c).
CONCLUSION
We have demonstrated how the rigorous analysis and
characterization of heat precipitation methods cannot only
remove the majority of HCPs from crude plant extract and thus
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represent a relevant simplification of subsequent DSP steps,
especially for target proteins that cannot be captured using
affinity-based methods, but also how heat treatment can increase
the recovery of product from biomass and the stability of
target proteins after extraction by inactivating host cell proteases
present in the crude extract. A prerequisite for the successful
application of these methods is the heat stability of the target
protein. Further investigation will be necessary to confirm the
functionality of the purified vaccine candidates C9S and FQS with
respect to the correct presentation of relevant epitopes in animal
immunization studies and subsequent in vitro parasite inhibition
assays.
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